---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-027837"
form_type: "8-K"
ticker: "CLNN"
cik: "0001822791"
company_name: "Clene Inc."
filed_at: "2026-08-14T12:35:24+00:00"
generated_at: "2026-08-14T12:40:09.916126+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Clene Q2 net loss $13.4M; NDA for CNM-Au8 in ALS expected early Q4 2026

## Summary
- NDA for CNM-Au8 in ALS under accelerated approval expected early Q4 2026; FDA confirmed data may support submission.
- Cash $9.7M at June 30 vs $5.2M at Dec 31; runway through late Q4 2026.
- Net loss $13.4M ($1.08/share) vs $7.4M ($0.78) in Q2 2025; other expense $8.1M on warrant/derivative fair value.
- R&D flat at $3.5M; G&A down to $1.9M from $2.4M.
- Closed $7M offering; extended convertible debt maturities to Aug 2027.

## SEC filing metadata
- accession: 0001437749-26-027837
- form_type: 8-K
- ticker: CLNN
- cik: 0001822791
- company_name: Clene Inc.
- filed_at: 2026-08-14T12:35:24+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1822791/000143774926027837/0001437749-26-027837-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1822791/000143774926027837/clnn20260524_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-027837
- JSON: https://secwatch.observer/filing/0001437749-26-027837.json
- Plain text: https://secwatch.observer/filing/0001437749-26-027837.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.